Digoxin:A systematic review in atrial fibrillation,congestive heart failure and post myocardial infarction
|
摘要
AIM: To review digoxin use in systolic congestive heart failure, atrial fibrillation, and after myocardial infarction. METHODS: A comprehensive Pub Med search was performed using the key words "digoxin and congestive heart failure", "digoxin and atrial fibrillation", "digoxin, atrial fibrillation and systolic congestive heart failure", and "digoxin and myocardial infarction". Only articles written in English were included in this study. We retained studies originating from randomized controlled trials, registries and included at least 500 patients. The studies included patients with atrial fibrillation or heart failure or myocardial infarction and had a significant proportion of patients(at least 5%) on digoxin. A table reviewing the different hazard ratios was developed based on the articles selected. Our primary endpoint was the overall mortality in the patients on digoxin vs those without digoxin, among patients with atrial fibrillation and also among patients with atrial fibrillation and systolic heart failure. We reviewed the most recent international guidelines to discuss current recommendations.RESULTS: A total of 18 studies were found that evaluated digoxin and overall mortality in different clinical settings including systolic congestive heart failure and normal sinus rhythm(n = 5), atrial fibrillation with and without systolic congestive heart failure(n = 9), and myocardial infarction(n = 4). Overall, patients with systolic congestive heart failure with normal sinus rhythm, digoxin appears to have a neutral effect on mortality especially if close digoxin level monitoring is employed. However, most of the observational studies evaluating digoxin use in atrial fibrillation without systolic congestive heart failure showed an increase in overall mortality when taking digoxin. In the studies evaluated in this systematic review, the data among patients with atrial fibrillation and systolic congestive heart failure, as well as post myocardial infarction were more controversial. The extent to which discrepancies among studies are based on statistical methods is currently unclear, as these studies' findings are generated by retrospective analyses that employed different techniques to address confounding. CONCLUSION: Based on the potential risks and benefits, as well as the presence of alternative drugs, there is a limited role for digoxin in the management of patients with normal sinus rhythm and congestive heart failure. Based on the retrospective studies reviewed there is a growing volume of data showing increased mortality in those with only atrial fibrillation. The pro-per role of digoxin is, however, less certain in other subgroups of patients, such as those with both atrial fibrillation and systolic congestive heart failure or after a myocardial infarction. Further studies may provide helpful information for such subgroups of patients.
AIM: To review digoxin use in systolic congestive heart failure, atrial fibrillation, and after myocardial infarction. METHODS: A comprehensive Pub Med search was performed using the key words "digoxin and congestive heart failure", "digoxin and atrial fibrillation", "digoxin, atrial fibrillation and systolic congestive heart failure", and "digoxin and myocardial infarction". Only articles written in English were included in this study. We retained studies originating from randomized controlled trials, registries and included at least 500 patients. The studies included patients with atrial fibrillation or heart failure or myocardial infarction and had a significant proportion of patients(at least 5%) on digoxin. A table reviewing the different hazard ratios was developed based on the articles selected. Our primary endpoint was the overall mortality in the patients on digoxin vs those without digoxin, among patients with atrial fibrillation and also among patients with atrial fibrillation and systolic heart failure. We reviewed the most recent international guidelines to discuss current recommendations.RESULTS: A total of 18 studies were found that evaluated digoxin and overall mortality in different clinical settings including systolic congestive heart failure and normal sinus rhythm(n = 5), atrial fibrillation with and without systolic congestive heart failure(n = 9), and myocardial infarction(n = 4). Overall, patients with systolic congestive heart failure with normal sinus rhythm, digoxin appears to have a neutral effect on mortality especially if close digoxin level monitoring is employed. However, most of the observational studies evaluating digoxin use in atrial fibrillation without systolic congestive heart failure showed an increase in overall mortality when taking digoxin. In the studies evaluated in this systematic review, the data among patients with atrial fibrillation and systolic congestive heart failure, as well as post myocardial infarction were more controversial. The extent to which discrepancies among studies are based on statistical methods is currently unclear, as these studies' findings are generated by retrospective analyses that employed different techniques to address confounding. CONCLUSION: Based on the potential risks and benefits, as well as the presence of alternative drugs, there is a limited role for digoxin in the management of patients with normal sinus rhythm and congestive heart failure. Based on the retrospective studies reviewed there is a growing volume of data showing increased mortality in those with only atrial fibrillation. The pro-per role of digoxin is, however, less certain in other subgroups of patients, such as those with both atrial fibrillation and systolic congestive heart failure or after a myocardial infarction. Further studies may provide helpful information for such subgroups of patients.
AIM: To review digoxin use in systolic congestive heart failure, atrial fibrillation, and after myocardial infarction. METHODS: A comprehensive Pub Med search was performed using the key words "digoxin and congestive heart failure", "digoxin and atrial fibrillation", "digoxin, atrial fibrillation and systolic congestive heart failure", and "digoxin and myocardial infarction". Only articles written in English were included in this study. We retained studies originating from randomized controlled trials, registries and included at least 500 patients. The studies included patients with atrial fibrillation or heart failure or myocardial infarction and had a significant proportion of patients(at least 5%) on digoxin. A table reviewing the different hazard ratios was developed based on the articles selected. Our primary endpoint was the overall mortality in the patients on digoxin vs those without digoxin, among patients with atrial fibrillation and also among patients with atrial fibrillation and systolic heart failure. We reviewed the most recent international guidelines to discuss current recommendations.RESULTS: A total of 18 studies were found that evaluated digoxin and overall mortality in different clinical settings including systolic congestive heart failure and normal sinus rhythm(n = 5), atrial fibrillation with and without systolic congestive heart failure(n = 9), and myocardial infarction(n = 4). Overall, patients with systolic congestive heart failure with normal sinus rhythm, digoxin appears to have a neutral effect on mortality especially if close digoxin level monitoring is employed. However, most of the observational studies evaluating digoxin use in atrial fibrillation without systolic congestive heart failure showed an increase in overall mortality when taking digoxin. In the studies evaluated in this systematic review, the data among patients with atrial fibrillation and systolic congestive heart failure, as well as post myocardial infarction were more controversial. The extent to which discrepancies among studies are based on statistical methods is currently unclear, as these studies' findings are generated by retrospective analyses that employed different techniques to address confounding. CONCLUSION: Based on the potential risks and benefits, as well as the presence of alternative drugs, there is a limited role for digoxin in the management of patients with normal sinus rhythm and congestive heart failure. Based on the retrospective studies reviewed there is a growing volume of data showing increased mortality in those with only atrial fibrillation. The pro-per role of digoxin is, however, less certain in other subgroups of patients, such as those with both atrial fibrillation and systolic congestive heart failure or after a myocardial infarction. Further studies may provide helpful information for such subgroups of patients.
引文
1 Digitalis Investigation Group.The effect of digoxin on mortality and morbidity in patients with heart failure.N Engl J Med 1997;336:525-533[PMID:9036306 DOI:10.1056/NEJM199702203360801]
2 Shah M,Avgil Tsadok M,Jackevicius CA,Essebag V,Behlouli H,Pilote L.Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients≥65 years of age with versus without heart failure.Am J Cardiol 2014;114:401-406[PMID:24950677DOI:10.1016/j.amjcard.2014.05.013]
3 Turakhia MP,Santangeli P,Winkelmayer WC,Xu X,Ullal AJ,Than CT,Schmitt S,Holmes TH,Frayne SM,Phibbs CS,Yang F,Hoang DD,Ho PM,Heidenreich PA.Increased mortality associated with digoxin in contemporary patients with atrial fibrillation:findings from the TREAT-AF study.J Am Coll Cardiol 2014;64:660-668[PMID:25125296 DOI:10.1016/j.jacc.2014.03.060]
4 Whitbeck MG,Charnigo RJ,Khairy P,Ziada K,Bailey AL,Zegarra MM,Shah J,Morales G,Macaulay T,Sorrell VL,Campbell CL,Gurley J,Anaya P,Nasr H,Bai R,Di Biase L,Booth DC,Jondeau G,Natale A,Roy D,Smyth S,Moliterno DJ,Elayi CS.Increased mortality among patients taking digoxin--analysis from the AFFIRM study.Eur Heart J 2013;34:1481-1488[PMID:23186806 DOI:10.1093/eurheartj/ehs348]
5 Maury P,Rollin A,Galinier M,Juilliére Y.Role of digoxin in controlling the ventricular rate during atrial fibrillation:a systematic review and rethinking.Research Reports in Clinical Cardiology2014;5:93-101[DOI:10.2147/RRCC.S44919]
6 Eichhorn EJ,Gheorghiade M.Digoxin.Prog Cardiovasc Dis 2002;44:251-266[PMID:12007081 DOI:10.1053/pcad.2002.31591]
7 Dec GW.Digoxin remains useful in the management of chronic heart failure.Med Clin North Am 2003;87:317-337[PMID:12693728 DOI:10.1016/S0025-7125(02)00172-4]
8 Chaggar PS,Shaw SM,Williams SG.Is foxglove effective in heart failure?Cardiovasc Ther 2015;33:236-241[PMID:25925484DOI:10.1111/1755-5922.12130]
9 Stucky MA,Goldberger ZD.Digoxin:its role in contemporary medicine.Postgrad Med J 2015;91:514-518[PMID:26265790DOI:10.1136/postgradmedj-2014-132937]
10 Packer M,Gheorghiade M,Young JB,Costantini PJ,Adams KF,Cody RJ,Smith LK,Van Voorhees L,Gourley LA,Jolly MK.Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.RADIANCE Study.N Engl J Med 1993;329:1-7[PMID:8505940DOI:10.1056/NEJM199307013290101]
11 Uretsky BF,Young JB,Shahidi FE,Yellen LG,Harrison MC,Jolly MK.Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure:results of the PROVED trial.PROVED Investigative Group.J Am Coll Cardiol 1993;22:955-962[PMID:8409069 DOI:10.1016/0735 -1097(93)90403-N]
12 Rathore SS,Curtis JP,Wang Y,Bristow MR,Krumholz HM.Association of serum digoxin concentration and outcomes in patients with heart failure.JAMA 2003;289:871-878[PMID:12588271 DOI:10.1001/jama.289.7.871]
13 Hood WB,Dans AL,Guyatt GH,Jaeschke R,Mc Murray JJ.Digitalis for treatment of congestive heart failure in patients in sinus rhythm:a systematic review and meta-analysis.J Card Fail 2004;10:155-164[PMID:15101028 DOI:10.1016/j.cardfail.2003.12.005]
14 Yancy CW,Jessup M,Bozkurt B,Butler J,Casey DE,Drazner MH,Fonarow GC,Geraci SA,Horwich T,Januzzi JL,Johnson MR,Kasper EK,Levy WC,Masoudi FA,Mc Bride PE,Mc Murray JJ,Mitchell JE,Peterson PN,Riegel B,Sam F,Stevenson LW,Tang WH,Tsai EJ,Wilkoff BL.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol 2013;62:e147-e239[PMID:23747642 DOI:10.1016/j.jacc.2013.05.019]
15 Mc Murray JJ,Adamopoulos S,Anker SD,Auricchio A,B?hm M,Dickstein K,Falk V,Filippatos G,Fonseca C,Gomez-Sanchez MA,Jaarsma T,K?ber L,Lip GY,Maggioni AP,Parkhomenko A,Pieske BM,Popescu BA,R?nnevik PK,Rutten FH,Schwitter J,Seferovic P,Stepinska J,Trindade PT,Voors AA,Zannad F,Zeiher A,Bax JJ,Baumgartner H,Ceconi C,Dean V,Deaton C,Fagard R,Funck-Brentano C,Hasdai D,Hoes A,Kirchhof P,Knuuti J,Kolh P,Mc Donagh T,Moulin C,Popescu BA,Reiner Z,Sechtem U,Sirnes PA,Tendera M,Torbicki A,Vahanian A,Windecker S,Mc Donagh T,Sechtem U,Bonet LA,Avraamides P,Ben Lamin HA,Brignole M,Coca A,Cowburn P,Dargie H,Elliott P,Flachskampf FA,Guida GF,Hardman S,Iung B,Merkely B,Mueller C,Nanas JN,Nielsen OW,Orn S,Parissis JT,Ponikowski P.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association(HFA)of the ESC.Eur J Heart Fail 2012;14:803-869[PMID:22828712DOI:10.1093/eurjhf/hfs105]
16 Wyse DG,Waldo AL,Di Marco JP,Domanski MJ,Rosenberg Y,Schron EB,Kellen JC,Greene HL,Mickel MC,Dalquist JE,Corley SD.A comparison of rate control and rhythm control in patients with atrial fibrillation.N Engl J Med 2002;347:1825-1833[PMID:12466506 DOI:10.1056/NEJMoa021328]
17 Van Gelder IC,Hagens VE,Bosker HA,Kingma JH,Kamp O,Kingma T,Said SA,Darmanata JI,Timmermans AJ,Tijssen JG,Crijns HJ.A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.N Engl J Med 2002;347:1834-1840[PMID:12466507 DOI:10.1056/NEJMoa021375]
18 Hohnloser SH,Kuck KH,Lilienthal J.Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation(PIAF):a randomised trial.Lancet 2000;356:1789-1794[PMID:11117910 DOI:10.1016/S0140-6736(00)03230-X]
19 Carlsson J,Miketic S,Windeler J,Cuneo A,Haun S,Micus S,Walter S,Tebbe U.Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation:the Strategies of Treatment of Atrial Fibrillation(STAF)study.J Am Coll Cardiol 2003;41:1690-1696[PMID:12767648 DOI:10.1016/S0735-1097(03)00332-2]
20 Opolski G,Torbicki A,Kosior DA,Szulc M,Wozakowska-Kaplon B,Kolodziej P,Achremczyk P.Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation:the results of the Polish How to Treat Chronic Atrial Fibrillation(HOT CAFE)Study.Chest 2004;126:476-486[PMID:15302734 DOI:10.1378/chest.126.2.476]
21 Roy D,Talajic M,Nattel S,Wyse DG,Dorian P,Lee KL,Bourassa MG,Arnold JM,Buxton AE,Camm AJ,Connolly SJ,Dubuc M,Ducharme A,Guerra PG,Hohnloser SH,Lambert J,Le Heuzey JY,O’Hara G,Pedersen OD,Rouleau JL,Singh BN,Stevenson LW,Stevenson WG,Thibault B,Waldo AL.Rhythm control versus rate control for atrial fibrillation and heart failure.N Engl J Med 2008;358:2667-2677[PMID:18565859 DOI:10.1056/NEJMoa0708789]
22 Heist EK,Mansour M,Ruskin JN.Rate control in atrial fibrillation:targets,methods,resynchronization considerations.Circulation 2011;124:2746-2755[PMID:22155996 DOI:10.1161/CIRCULATIONAHA.111.019919]
23 Corley SD,Epstein AE,Di Marco JP,Domanski MJ,Geller N,Greene HL,Josephson RA,Kellen JC,Klein RC,Krahn AD,Mickel M,Mitchell LB,Nelson JD,Rosenberg Y,Schron E,Shemanski L,Waldo AL,Wyse DG.Relationships between sinus rhythm,treatment,and survival in the Atrial Fibrillation FollowUp Investigation of Rhythm Management(AFFIRM)Study.Circulation 2004;109:1509-1513[PMID:15007003 DOI:10 .1161/01.CIR.0000121736.16643.11]
24 Elayi CS,Whitbeck MG,Charnigo R,Shah J,Macaulay TE,Morales G,Gurley JC,Kakavand B,Thal S,Ching CK,Khaykin Y,Verma A,Barrett C,Bai R,Di Biase L,Patwardhan A,Moliterno DJ,Natale A.Is there an association between external cardioversions and long-term mortality and morbidity?Insights from the Atrial Fibrillation Follow-up Investigation of Rhythm Management study.Circ Arrhythm Electrophysiol 2011;4:465-469[PMID:21511994 DOI:10.1161/CIRCEP.110.960591]
25 Hallberg P,Lindb?ck J,Lindahl B,Stenestrand U,Melhus H.Digoxin and mortality in atrial fibrillation:a prospective cohort study.Eur J Clin Pharmacol 2007;63:959-971[PMID:17684738DOI:10.1007/s00228-007-0346-9]
26 Gheorghiade M,Fonarow GC,van Veldhuisen DJ,Cleland JG,Butler J,Epstein AE,Patel K,Aban IB,Aronow WS,Anker SD,Ahmed A.Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin:findings from post hoc propensity-matched analysis of the AFFIRM trial.Eur Heart J2013;34:1489-1497[PMID:23592708 DOI:10.1093/eurheartj/eht120]
27 Murphy SA.When‘digoxin use’is not the same as‘digoxin use’:lessons from the AFFIRM trial.Eur Heart J 2013;34:1465-1467[PMID:23592709 DOI:10.1093/eurheartj/eht087]
28 Chao TF,Liu CJ,Chen SJ,Wang KL,Lin YJ,Chang SL,Lo LW,Hu YF,Tuan TC,Chen TJ,Chiang CE,Chen SA.Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation?A nationwide population-based cohort study.Can J Cardiol 2014;30:1190-1195[PMID:25262860 DOI:10.1016/j.cjca.2014.05.009]
29 Freeman JV,Reynolds K,Fang M,Udaltsova N,Steimle A,Pomernacki NK,Borowsky LH,Harrison TN,Singer DE,Go AS.Digoxin and risk of death in adults with atrial fibrillation:the ATRIA-CVRN study.Circ Arrhythm Electrophysiol 2015;8:49-58[PMID:25414270 DOI:10.1161/CIRCEP.114.002292]
30 Washam JB,Stevens SR,Lokhnygina Y,Halperin JL,Breithardt G,Singer DE,Mahaffey KW,Hankey GJ,Berkowitz SD,Nessel CC,Fox KA,Califf RM,Piccini JP,Patel MR.Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes:a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation(ROCKET AF).Lancet 2015;385:2363-2370[PMID:25749644DOI:10.1016/S0140-6736(14)61836-5]
31 Gjesdal K,Feyzi J,Olsson SB.Digitalis:a dangerous drug in atrial fibrillation?An analysis of the SPORTIF III and V data.Heart 2008;94:191-196[PMID:17483128 DOI:10.1136/hrt.2006.108399]
32 Friberg L,Hammar N,Rosenqvist M.Digoxin in atrial fibrillation:report from the Stockholm Cohort study of Atrial Fibrillation(SCAF).Heart 2010;96:275-280[PMID:19710030 DOI:10.1136/hrt.2009.175786]
33 Pastori D,Farcomeni A,Bucci T,Cangemi R,Ciacci P,Vicario T,Violi F,Pignatelli P.Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation.Int J Cardiol 2015;180:1-5[PMID:25460369DOI:10.1016/j.ijcard.2014.11.112]
34 Rodríguez-Ma?ero M,Otero-Ravi?a F,García-Seara J,ZugazaGurruchaga L,Rodríguez-García JM,Blanco-Rodríguez R,Turrado Turrado V,Fernández-Villaverde JM,Vidal-Pérez RC,GonzálezJuanatey JR.Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin:results from the AFBAR study.Rev Esp Cardiol(Engl Ed)2014;67:890-897[PMID:25443813 DOI:10 .1016/j.rec.2014.01.014]
35 Mulder BA,Van Veldhuisen DJ,Crijns HJ,Tijssen JG,Hillege HL,Alings M,Rienstra M,Van den Berg MP,Van Gelder IC.Digoxin in patients with permanent atrial fibrillation:data from the RACE II study.Heart Rhythm 2014;11:1543-1550[PMID:24924587 DOI:10 .1016/j.hrthm.2014.06.007]
36 January CT,Wann LS,Alpert JS,Calkins H,Cigarroa JE,Cleveland JC,Conti JB,Ellinor PT,Ezekowitz MD,Field ME,Murray KT,Sacco RL,Stevenson WG,Tchou PJ,Tracy CM,Yancy CW.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.J Am Coll Cardiol 2014;64 :e1-76[PMID:24685669 DOI:10.1016/j.jacc.2014.03.022]
37 Camm AJ,Kirchhof P,Lip GY,Schotten U,Savelieva I,Ernst S,Van Gelder IC,Al-Attar N,Hindricks G,Prendergast B,Heidbuchel H,Alfieri O,Angelini A,Atar D,Colonna P,De Caterina R,De Sutter J,Goette A,Gorenek B,Heldal M,Hohloser SH,Kolh P,Le Heuzey JY,Ponikowski P,Rutten FH.Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC).Eur Heart J 2010;31:2369-2429[PMID:20802247 DOI:10.1093/eurheartj/ehq278]
38 Antman EM,Anbe DT,Armstrong PW,Bates ER,Green LA,Hand M,Hochman JS,Krumholz HM,Kushner FG,Lamas GA,Mullany CJ,Ornato JP,Pearle DL,Sloan MA,Smith SC,Alpert JS,Anderson JL,Faxon DP,Fuster V,Gibbons RJ,Gregoratos G,Halperin JL,Hiratzka LF,Hunt SA,Jacobs AK,Ornato JP.ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction;A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).J Am Coll Cardiol 2004;44:E1-E211[PMID:15358047 DOI:10.1016/j.jacc.2004.07.014]
39 Steg PG,James SK,Atar D,Badano LP,Bl?mstrom-Lundqvist C,Borger MA,Di Mario C,Dickstein K,Ducrocq G,FernandezAviles F,Gershlick AH,Giannuzzi P,Halvorsen S,Huber K,Juni P,Kastrati A,Knuuti J,Lenzen MJ,Mahaffey KW,Valgimigli M,van‘t Hof A,Widimsky P,Zahger D.ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation.Eur Heart J 2012;33:2569-2619[PMID:22922416 DOI:10.1093/eurheartj/ehs215]
40 Garcia-Rubira JC,Calvo-Taracido M,Francisco-Aparicio F,Almendro-Delia M,Recio-Mayoral A,Reina Toral A,AramburuBodas O,Gallego García de Vinuesa P,Cruz Fernández JM,Alcántara AG,Hidalgo-Urbano R.The previous use of digoxin does not worsen early outcome of acute coronary syndromes:an analysis of the ARIAM Registry.Intern Emerg Med 2014;9:759-765[PMID:24352793 DOI:10.1007/s11739-013-1032-9]
41 K?ber L,Torp-Pedersen C,Gadsb?ll N,Hildebrandt P,H?ilundCarlsen PF.Is digoxin an independent risk factor for long-term mortality after acute myocardial infarction?Eur Heart J 1994;15:382-388[PMID:8013513]
42 Reicher-Reiss H,Jonas M,Boyko V,Shotan A,Goldbourt U,Behar S.Are coronary patients at higher risk with digoxin therapy?An ongoing controversy.Int J Cardiol 1999;68:137-143[PMID:10189000 DOI:10.1016/S0167-5273(98)00364-7]
43 Leor J,Goldbourt U,Behar S,Boyko V,Reicher-Reiss H,Kaplinsky E,Rabinowitz B.Digoxin and mortality in survivors of acute myocardial infarction:observations in patients at low and intermediate risk.The SPRINT Study Group.Secondary PreventionReinfarction Israeli Nifedipine Trial.Cardiovasc Drugs Ther 1995;9:609-617[PMID:8547212 DOI:10.1007/BF00878094]
44 Hood WB,Dans AL,Guyatt GH,Jaeschke R,Mc Murray JJ.Digitalis for treatment of congestive heart failure in patients in sinus rhythm.Cochrane Database Syst Rev 2004;(2):CD002901[PMID:15106182 DOI:10.1002/14651858.CD002901.pub2]
45 Freeman JV,Yang J,Sung SH,Hlatky MA,Go AS.Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure.Circ Cardiovasc Qual Outcomes 2013;6:525-533[PMID:24021697 DOI:10.1161/CIRCOUTCOMES.111.000079]
46 Ahmed A,Bourge RC,Fonarow GC,Patel K,Morgan CJ,Fleg JL,Aban IB,Love TE,Yancy CW,Deedwania P,van Veldhuisen DJ,Filippatos GS,Anker SD,Allman RM.Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure.Am J Med 2014;127:61-70[PMID:24257326 DOI:10.1016/j.amjmed.2013.08.027]
47 Georgiopoulou VV,Kalogeropoulos AP,Giamouzis G,Agha SA,Rashad MA,Waheed S,Laskar S,Smith AL,Butler J.Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy.Circ Heart Fail 2009;2:90-97[PMID:19808323 DOI:10.1161/CIRCHEARTFAILURE.108.807032]
48 Mc Murray JJ,Packer M,Desai AS,Gong J,Lefkowitz MP,Rizkala AR,Rouleau JL,Shi VC,Solomon SD,Swedberg K,Zile MR.Angiotensin-neprilysin inhibition versus enalapril in heart failure.N Engl J Med 2014;371:993-1004[PMID:25176015 DOI:10 .1056/NEJMoa1409077]
49 Swedberg K,Komajda M,B?hm M,Borer JS,Ford I,DubostBrama A,Lerebours G,Tavazzi L.Ivabradine and outcomes in chronic heart failure(SHIFT):a randomised placebo-controlled study.Lancet 2010;376:875-885[PMID:20801500 DOI:10.1016/S0140-6736(10)61198-1]
50 Vamos M,Erath JW,Hohnloser SH.Digoxin-associated mortality:a systematic review and meta-analysis of the literature.Eur Heart J 2015;36:1831-1838[PMID:25939649 DOI:10.1093/eurheartj/ehv143]
51 Fauchier L,Laborie G,Clementy N.Effect of digoxin on all-cause mortality in patients with atrial fibrillation in a population-based cohort study.Heart Failure Congress;2015 May 24;Seville,Spain
2 Shah M,Avgil Tsadok M,Jackevicius CA,Essebag V,Behlouli H,Pilote L.Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients≥65 years of age with versus without heart failure.Am J Cardiol 2014;114:401-406[PMID:24950677DOI:10.1016/j.amjcard.2014.05.013]
3 Turakhia MP,Santangeli P,Winkelmayer WC,Xu X,Ullal AJ,Than CT,Schmitt S,Holmes TH,Frayne SM,Phibbs CS,Yang F,Hoang DD,Ho PM,Heidenreich PA.Increased mortality associated with digoxin in contemporary patients with atrial fibrillation:findings from the TREAT-AF study.J Am Coll Cardiol 2014;64:660-668[PMID:25125296 DOI:10.1016/j.jacc.2014.03.060]
4 Whitbeck MG,Charnigo RJ,Khairy P,Ziada K,Bailey AL,Zegarra MM,Shah J,Morales G,Macaulay T,Sorrell VL,Campbell CL,Gurley J,Anaya P,Nasr H,Bai R,Di Biase L,Booth DC,Jondeau G,Natale A,Roy D,Smyth S,Moliterno DJ,Elayi CS.Increased mortality among patients taking digoxin--analysis from the AFFIRM study.Eur Heart J 2013;34:1481-1488[PMID:23186806 DOI:10.1093/eurheartj/ehs348]
5 Maury P,Rollin A,Galinier M,Juilliére Y.Role of digoxin in controlling the ventricular rate during atrial fibrillation:a systematic review and rethinking.Research Reports in Clinical Cardiology2014;5:93-101[DOI:10.2147/RRCC.S44919]
6 Eichhorn EJ,Gheorghiade M.Digoxin.Prog Cardiovasc Dis 2002;44:251-266[PMID:12007081 DOI:10.1053/pcad.2002.31591]
7 Dec GW.Digoxin remains useful in the management of chronic heart failure.Med Clin North Am 2003;87:317-337[PMID:12693728 DOI:10.1016/S0025-7125(02)00172-4]
8 Chaggar PS,Shaw SM,Williams SG.Is foxglove effective in heart failure?Cardiovasc Ther 2015;33:236-241[PMID:25925484DOI:10.1111/1755-5922.12130]
9 Stucky MA,Goldberger ZD.Digoxin:its role in contemporary medicine.Postgrad Med J 2015;91:514-518[PMID:26265790DOI:10.1136/postgradmedj-2014-132937]
10 Packer M,Gheorghiade M,Young JB,Costantini PJ,Adams KF,Cody RJ,Smith LK,Van Voorhees L,Gourley LA,Jolly MK.Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.RADIANCE Study.N Engl J Med 1993;329:1-7[PMID:8505940DOI:10.1056/NEJM199307013290101]
11 Uretsky BF,Young JB,Shahidi FE,Yellen LG,Harrison MC,Jolly MK.Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure:results of the PROVED trial.PROVED Investigative Group.J Am Coll Cardiol 1993;22:955-962[PMID:8409069 DOI:10.1016/0735 -1097(93)90403-N]
12 Rathore SS,Curtis JP,Wang Y,Bristow MR,Krumholz HM.Association of serum digoxin concentration and outcomes in patients with heart failure.JAMA 2003;289:871-878[PMID:12588271 DOI:10.1001/jama.289.7.871]
13 Hood WB,Dans AL,Guyatt GH,Jaeschke R,Mc Murray JJ.Digitalis for treatment of congestive heart failure in patients in sinus rhythm:a systematic review and meta-analysis.J Card Fail 2004;10:155-164[PMID:15101028 DOI:10.1016/j.cardfail.2003.12.005]
14 Yancy CW,Jessup M,Bozkurt B,Butler J,Casey DE,Drazner MH,Fonarow GC,Geraci SA,Horwich T,Januzzi JL,Johnson MR,Kasper EK,Levy WC,Masoudi FA,Mc Bride PE,Mc Murray JJ,Mitchell JE,Peterson PN,Riegel B,Sam F,Stevenson LW,Tang WH,Tsai EJ,Wilkoff BL.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol 2013;62:e147-e239[PMID:23747642 DOI:10.1016/j.jacc.2013.05.019]
15 Mc Murray JJ,Adamopoulos S,Anker SD,Auricchio A,B?hm M,Dickstein K,Falk V,Filippatos G,Fonseca C,Gomez-Sanchez MA,Jaarsma T,K?ber L,Lip GY,Maggioni AP,Parkhomenko A,Pieske BM,Popescu BA,R?nnevik PK,Rutten FH,Schwitter J,Seferovic P,Stepinska J,Trindade PT,Voors AA,Zannad F,Zeiher A,Bax JJ,Baumgartner H,Ceconi C,Dean V,Deaton C,Fagard R,Funck-Brentano C,Hasdai D,Hoes A,Kirchhof P,Knuuti J,Kolh P,Mc Donagh T,Moulin C,Popescu BA,Reiner Z,Sechtem U,Sirnes PA,Tendera M,Torbicki A,Vahanian A,Windecker S,Mc Donagh T,Sechtem U,Bonet LA,Avraamides P,Ben Lamin HA,Brignole M,Coca A,Cowburn P,Dargie H,Elliott P,Flachskampf FA,Guida GF,Hardman S,Iung B,Merkely B,Mueller C,Nanas JN,Nielsen OW,Orn S,Parissis JT,Ponikowski P.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association(HFA)of the ESC.Eur J Heart Fail 2012;14:803-869[PMID:22828712DOI:10.1093/eurjhf/hfs105]
16 Wyse DG,Waldo AL,Di Marco JP,Domanski MJ,Rosenberg Y,Schron EB,Kellen JC,Greene HL,Mickel MC,Dalquist JE,Corley SD.A comparison of rate control and rhythm control in patients with atrial fibrillation.N Engl J Med 2002;347:1825-1833[PMID:12466506 DOI:10.1056/NEJMoa021328]
17 Van Gelder IC,Hagens VE,Bosker HA,Kingma JH,Kamp O,Kingma T,Said SA,Darmanata JI,Timmermans AJ,Tijssen JG,Crijns HJ.A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.N Engl J Med 2002;347:1834-1840[PMID:12466507 DOI:10.1056/NEJMoa021375]
18 Hohnloser SH,Kuck KH,Lilienthal J.Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation(PIAF):a randomised trial.Lancet 2000;356:1789-1794[PMID:11117910 DOI:10.1016/S0140-6736(00)03230-X]
19 Carlsson J,Miketic S,Windeler J,Cuneo A,Haun S,Micus S,Walter S,Tebbe U.Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation:the Strategies of Treatment of Atrial Fibrillation(STAF)study.J Am Coll Cardiol 2003;41:1690-1696[PMID:12767648 DOI:10.1016/S0735-1097(03)00332-2]
20 Opolski G,Torbicki A,Kosior DA,Szulc M,Wozakowska-Kaplon B,Kolodziej P,Achremczyk P.Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation:the results of the Polish How to Treat Chronic Atrial Fibrillation(HOT CAFE)Study.Chest 2004;126:476-486[PMID:15302734 DOI:10.1378/chest.126.2.476]
21 Roy D,Talajic M,Nattel S,Wyse DG,Dorian P,Lee KL,Bourassa MG,Arnold JM,Buxton AE,Camm AJ,Connolly SJ,Dubuc M,Ducharme A,Guerra PG,Hohnloser SH,Lambert J,Le Heuzey JY,O’Hara G,Pedersen OD,Rouleau JL,Singh BN,Stevenson LW,Stevenson WG,Thibault B,Waldo AL.Rhythm control versus rate control for atrial fibrillation and heart failure.N Engl J Med 2008;358:2667-2677[PMID:18565859 DOI:10.1056/NEJMoa0708789]
22 Heist EK,Mansour M,Ruskin JN.Rate control in atrial fibrillation:targets,methods,resynchronization considerations.Circulation 2011;124:2746-2755[PMID:22155996 DOI:10.1161/CIRCULATIONAHA.111.019919]
23 Corley SD,Epstein AE,Di Marco JP,Domanski MJ,Geller N,Greene HL,Josephson RA,Kellen JC,Klein RC,Krahn AD,Mickel M,Mitchell LB,Nelson JD,Rosenberg Y,Schron E,Shemanski L,Waldo AL,Wyse DG.Relationships between sinus rhythm,treatment,and survival in the Atrial Fibrillation FollowUp Investigation of Rhythm Management(AFFIRM)Study.Circulation 2004;109:1509-1513[PMID:15007003 DOI:10 .1161/01.CIR.0000121736.16643.11]
24 Elayi CS,Whitbeck MG,Charnigo R,Shah J,Macaulay TE,Morales G,Gurley JC,Kakavand B,Thal S,Ching CK,Khaykin Y,Verma A,Barrett C,Bai R,Di Biase L,Patwardhan A,Moliterno DJ,Natale A.Is there an association between external cardioversions and long-term mortality and morbidity?Insights from the Atrial Fibrillation Follow-up Investigation of Rhythm Management study.Circ Arrhythm Electrophysiol 2011;4:465-469[PMID:21511994 DOI:10.1161/CIRCEP.110.960591]
25 Hallberg P,Lindb?ck J,Lindahl B,Stenestrand U,Melhus H.Digoxin and mortality in atrial fibrillation:a prospective cohort study.Eur J Clin Pharmacol 2007;63:959-971[PMID:17684738DOI:10.1007/s00228-007-0346-9]
26 Gheorghiade M,Fonarow GC,van Veldhuisen DJ,Cleland JG,Butler J,Epstein AE,Patel K,Aban IB,Aronow WS,Anker SD,Ahmed A.Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin:findings from post hoc propensity-matched analysis of the AFFIRM trial.Eur Heart J2013;34:1489-1497[PMID:23592708 DOI:10.1093/eurheartj/eht120]
27 Murphy SA.When‘digoxin use’is not the same as‘digoxin use’:lessons from the AFFIRM trial.Eur Heart J 2013;34:1465-1467[PMID:23592709 DOI:10.1093/eurheartj/eht087]
28 Chao TF,Liu CJ,Chen SJ,Wang KL,Lin YJ,Chang SL,Lo LW,Hu YF,Tuan TC,Chen TJ,Chiang CE,Chen SA.Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation?A nationwide population-based cohort study.Can J Cardiol 2014;30:1190-1195[PMID:25262860 DOI:10.1016/j.cjca.2014.05.009]
29 Freeman JV,Reynolds K,Fang M,Udaltsova N,Steimle A,Pomernacki NK,Borowsky LH,Harrison TN,Singer DE,Go AS.Digoxin and risk of death in adults with atrial fibrillation:the ATRIA-CVRN study.Circ Arrhythm Electrophysiol 2015;8:49-58[PMID:25414270 DOI:10.1161/CIRCEP.114.002292]
30 Washam JB,Stevens SR,Lokhnygina Y,Halperin JL,Breithardt G,Singer DE,Mahaffey KW,Hankey GJ,Berkowitz SD,Nessel CC,Fox KA,Califf RM,Piccini JP,Patel MR.Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes:a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation(ROCKET AF).Lancet 2015;385:2363-2370[PMID:25749644DOI:10.1016/S0140-6736(14)61836-5]
31 Gjesdal K,Feyzi J,Olsson SB.Digitalis:a dangerous drug in atrial fibrillation?An analysis of the SPORTIF III and V data.Heart 2008;94:191-196[PMID:17483128 DOI:10.1136/hrt.2006.108399]
32 Friberg L,Hammar N,Rosenqvist M.Digoxin in atrial fibrillation:report from the Stockholm Cohort study of Atrial Fibrillation(SCAF).Heart 2010;96:275-280[PMID:19710030 DOI:10.1136/hrt.2009.175786]
33 Pastori D,Farcomeni A,Bucci T,Cangemi R,Ciacci P,Vicario T,Violi F,Pignatelli P.Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation.Int J Cardiol 2015;180:1-5[PMID:25460369DOI:10.1016/j.ijcard.2014.11.112]
34 Rodríguez-Ma?ero M,Otero-Ravi?a F,García-Seara J,ZugazaGurruchaga L,Rodríguez-García JM,Blanco-Rodríguez R,Turrado Turrado V,Fernández-Villaverde JM,Vidal-Pérez RC,GonzálezJuanatey JR.Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin:results from the AFBAR study.Rev Esp Cardiol(Engl Ed)2014;67:890-897[PMID:25443813 DOI:10 .1016/j.rec.2014.01.014]
35 Mulder BA,Van Veldhuisen DJ,Crijns HJ,Tijssen JG,Hillege HL,Alings M,Rienstra M,Van den Berg MP,Van Gelder IC.Digoxin in patients with permanent atrial fibrillation:data from the RACE II study.Heart Rhythm 2014;11:1543-1550[PMID:24924587 DOI:10 .1016/j.hrthm.2014.06.007]
36 January CT,Wann LS,Alpert JS,Calkins H,Cigarroa JE,Cleveland JC,Conti JB,Ellinor PT,Ezekowitz MD,Field ME,Murray KT,Sacco RL,Stevenson WG,Tchou PJ,Tracy CM,Yancy CW.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.J Am Coll Cardiol 2014;64 :e1-76[PMID:24685669 DOI:10.1016/j.jacc.2014.03.022]
37 Camm AJ,Kirchhof P,Lip GY,Schotten U,Savelieva I,Ernst S,Van Gelder IC,Al-Attar N,Hindricks G,Prendergast B,Heidbuchel H,Alfieri O,Angelini A,Atar D,Colonna P,De Caterina R,De Sutter J,Goette A,Gorenek B,Heldal M,Hohloser SH,Kolh P,Le Heuzey JY,Ponikowski P,Rutten FH.Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC).Eur Heart J 2010;31:2369-2429[PMID:20802247 DOI:10.1093/eurheartj/ehq278]
38 Antman EM,Anbe DT,Armstrong PW,Bates ER,Green LA,Hand M,Hochman JS,Krumholz HM,Kushner FG,Lamas GA,Mullany CJ,Ornato JP,Pearle DL,Sloan MA,Smith SC,Alpert JS,Anderson JL,Faxon DP,Fuster V,Gibbons RJ,Gregoratos G,Halperin JL,Hiratzka LF,Hunt SA,Jacobs AK,Ornato JP.ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction;A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).J Am Coll Cardiol 2004;44:E1-E211[PMID:15358047 DOI:10.1016/j.jacc.2004.07.014]
39 Steg PG,James SK,Atar D,Badano LP,Bl?mstrom-Lundqvist C,Borger MA,Di Mario C,Dickstein K,Ducrocq G,FernandezAviles F,Gershlick AH,Giannuzzi P,Halvorsen S,Huber K,Juni P,Kastrati A,Knuuti J,Lenzen MJ,Mahaffey KW,Valgimigli M,van‘t Hof A,Widimsky P,Zahger D.ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation.Eur Heart J 2012;33:2569-2619[PMID:22922416 DOI:10.1093/eurheartj/ehs215]
40 Garcia-Rubira JC,Calvo-Taracido M,Francisco-Aparicio F,Almendro-Delia M,Recio-Mayoral A,Reina Toral A,AramburuBodas O,Gallego García de Vinuesa P,Cruz Fernández JM,Alcántara AG,Hidalgo-Urbano R.The previous use of digoxin does not worsen early outcome of acute coronary syndromes:an analysis of the ARIAM Registry.Intern Emerg Med 2014;9:759-765[PMID:24352793 DOI:10.1007/s11739-013-1032-9]
41 K?ber L,Torp-Pedersen C,Gadsb?ll N,Hildebrandt P,H?ilundCarlsen PF.Is digoxin an independent risk factor for long-term mortality after acute myocardial infarction?Eur Heart J 1994;15:382-388[PMID:8013513]
42 Reicher-Reiss H,Jonas M,Boyko V,Shotan A,Goldbourt U,Behar S.Are coronary patients at higher risk with digoxin therapy?An ongoing controversy.Int J Cardiol 1999;68:137-143[PMID:10189000 DOI:10.1016/S0167-5273(98)00364-7]
43 Leor J,Goldbourt U,Behar S,Boyko V,Reicher-Reiss H,Kaplinsky E,Rabinowitz B.Digoxin and mortality in survivors of acute myocardial infarction:observations in patients at low and intermediate risk.The SPRINT Study Group.Secondary PreventionReinfarction Israeli Nifedipine Trial.Cardiovasc Drugs Ther 1995;9:609-617[PMID:8547212 DOI:10.1007/BF00878094]
44 Hood WB,Dans AL,Guyatt GH,Jaeschke R,Mc Murray JJ.Digitalis for treatment of congestive heart failure in patients in sinus rhythm.Cochrane Database Syst Rev 2004;(2):CD002901[PMID:15106182 DOI:10.1002/14651858.CD002901.pub2]
45 Freeman JV,Yang J,Sung SH,Hlatky MA,Go AS.Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure.Circ Cardiovasc Qual Outcomes 2013;6:525-533[PMID:24021697 DOI:10.1161/CIRCOUTCOMES.111.000079]
46 Ahmed A,Bourge RC,Fonarow GC,Patel K,Morgan CJ,Fleg JL,Aban IB,Love TE,Yancy CW,Deedwania P,van Veldhuisen DJ,Filippatos GS,Anker SD,Allman RM.Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure.Am J Med 2014;127:61-70[PMID:24257326 DOI:10.1016/j.amjmed.2013.08.027]
47 Georgiopoulou VV,Kalogeropoulos AP,Giamouzis G,Agha SA,Rashad MA,Waheed S,Laskar S,Smith AL,Butler J.Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy.Circ Heart Fail 2009;2:90-97[PMID:19808323 DOI:10.1161/CIRCHEARTFAILURE.108.807032]
48 Mc Murray JJ,Packer M,Desai AS,Gong J,Lefkowitz MP,Rizkala AR,Rouleau JL,Shi VC,Solomon SD,Swedberg K,Zile MR.Angiotensin-neprilysin inhibition versus enalapril in heart failure.N Engl J Med 2014;371:993-1004[PMID:25176015 DOI:10 .1056/NEJMoa1409077]
49 Swedberg K,Komajda M,B?hm M,Borer JS,Ford I,DubostBrama A,Lerebours G,Tavazzi L.Ivabradine and outcomes in chronic heart failure(SHIFT):a randomised placebo-controlled study.Lancet 2010;376:875-885[PMID:20801500 DOI:10.1016/S0140-6736(10)61198-1]
50 Vamos M,Erath JW,Hohnloser SH.Digoxin-associated mortality:a systematic review and meta-analysis of the literature.Eur Heart J 2015;36:1831-1838[PMID:25939649 DOI:10.1093/eurheartj/ehv143]
51 Fauchier L,Laborie G,Clementy N.Effect of digoxin on all-cause mortality in patients with atrial fibrillation in a population-based cohort study.Heart Failure Congress;2015 May 24;Seville,Spain